Skip to main content

Table 3 Laboratory outcome measures during randomised treatment phase presented as average [mean (SE)] changes from baseline during weeks 0 – 24 as measured by AUCMB

From: Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial

 

Placebo

Active

p

HTLV-I proviral loada (log10 copies/105 PBMCs)

+0.03 (0.10)

+0.05 (0.13)

0.92

Total Lymphocytesb (106/L)

+148.2 (58.0)

-159.3 (146.7)

0.07

CD3 Lymphocytesb (106/L)

+98.4 (63.4)

-23.2 (151.3)

0.47

CD3b %

+0.2 (2.8)

+4.3 (2.6)

0.14

CD4b Lymphocytes (106/L)

+32.6 (33.1)

+10.4 (98.7)

0.55

CD4b %

-1.2 (0.9)

+4.7 (1.8)

0.01

CD8b Lymphocytes (106/L)

+65.8 (31.3)

-38.1 (60.7)

0.15

CD8b %

+1.4 (1.2)

+1.4 (1.9)

0.99

CD25a %

-0.8 (1.8)

+0.3 (0.8)

0.58

CD69a %

+0.4 (1.3)

+1.2 (1.8)

0.73

CD71a%

-0.3 (1.0)

-0.2 (1.9)

0.97

HLA-DR%

-4.85 (4.0)

+3.59 (2.4)

0.42

  1. a Data only available on n = 6 in placebo group and n = 7 in active group due to missing baseline data
  2. b Data only available on n = 7 in placebo group and n = 7 in active group due to missing baseline data